Summary:
A new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes in lymphoma patients, offering a non-invasive, cost-effective alternative to traditional imaging.

Takeaways:

  • Multi-omics innovation: SeekInClarity combines genomic, epigenetic, and proteomic data to generate a molecular tumor burden (MTB) score that correlates with disease stage and prognosis.
  • Predictive superiority: The test outperformed traditional biomarkers and matched PET/CT as an independent predictor of treatment outcomes.
  • Clinical impact: SeekInClarity identified high-risk non-responders among patients with positive PET/CT results, highlighting its potential for earlier and more precise intervention.

A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinicians monitor treatment response.

Study Highlights

  • Innovative Approach: The SeekInClarity test integrates genomic, epigenetic, and proteomic signals from blood samples to calculate a molecular tumor burden (MTB) score, offering a non-invasive alternative to traditional imaging-based assessments.
  • Clinical Validation: In a cohort of 116 newly diagnosed lymphoma patients, higher MTB scores strongly correlated with advanced tumor stage. Patients whose MTB status remained positive after two treatment cycles had significantly worse progression-free and overall survival.
  • Superior Risk Stratification: The study found that molecular response, as measured by SeekInClarity, and interim PET/CT were the only independent predictors of treatment outcome—outperforming established clinical biomarkers such as B2M and LDH.
  • Added Value Beyond Imaging: Among patients with interim PET/CT response, SeekInClarity identified a subgroup of molecular non-responders who were at substantially higher risk of disease progression, particularly in aggressive lymphoma subtypes.

Clinical Impact of SeekInClarity

Current standards for monitoring lymphoma rely on PET-CT or CT imaging, which can be costly and have limitations in sensitivity. The SeekInClarity assay provides a cost-effective, pan-indication blood test that can refine risk stratification and enable earlier intervention for patients unlikely to respond to standard therapies.

“Our findings underscore the clinical value of integrating multi-omics liquid biopsy approaches like SeekInClarity into routine lymphoma management,” says Dr. Mao Mao, corresponding author and Founder & CEO at SeekIn Inc. “This tool can identify high-risk patients earlier and more accurately than current methods, guiding more personalized treatment decisions.” The study was a collaborative effort involving leading hospitals in China.

About the Study

The study prospectively enrolled 116 lymphoma patients from two major cancer centers in China. Blood samples were collected before and after two cycles of treatment to assess changes in the MTB score. The results were validated against interim PET/CT imaging and standard clinical biomarkers. SeekInClarity’s molecular response framework demonstrated robust predictive power for both progression-free and overall survival, especially in aggressive B-cell and NK/T-cell lymphomas.

Looking Ahead

This research paves the way for broader adoption of blood-based multi-omics monitoring in lymphoma and potentially other cancers, offering clinicians a powerful new tool to optimize patient outcomes.

Featured Image: Natalia Dobrovolska | Dreamstime.com